Drug makers seek to set record straight on GLP-1, DPP-4 pancreatic findings
This article was originally published in Scrip
The only way to ever really get to the bottom of whether so-called incretin mimetic therapies – glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors – trigger pancreatitis and precancerous cellular changes in patients with Type II diabetes will be to conduct adequately powered, long-term epidemiological studies, according to Dr Solomon Iyasu, director of the FDA's Division of Epidemiology.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.